Risk factors for severe radiation-induced oral mucositis in patients with oral cancer.
Oral cancer
Oral mucositis
Pilocarpine
Radiotherapy
Risk factors
Journal
Journal of dental sciences
ISSN: 2213-8862
Titre abrégé: J Dent Sci
Pays: Netherlands
ID NLM: 101293181
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
02
01
2021
revised:
09
01
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
7
9
2021
Statut:
ppublish
Résumé
Radiotherapy for head and neck cancer often causes severe oral mucositis. The purpose of this retrospective study was to further examine the risk factors for developing severe oral mucositis in patients with oral cancer undergoing radiotherapy as a compliment to a previous study performed by our group. A total of 181 patients with oral cancer undergoing radiotherapy were enrolled in the study. The association between a number of potential risk factors and grade 3 oral mucositis were analyzed using the cox proportional hazard model and a logistic regression analysis. Grade 3 oral mucositis occurred in 56 patients. The cox proportional hazard model analysis revealed that those with lower hemoglobin levels, concurrent cisplatin and cetuximab administration, and a larger number of teeth showed a significantly higher incidence of severe oral mucositis. Logistic regression analysis revealed that patients who had lower hemoglobin levels, received concurrent cisplatin or cetuximab treatment, and were not administered pilocarpine showed a significantly higher incidence of severe oral mucositis. The presence of teeth may stimulate the oral mucosa and become a risk factor for mucositis, and the administration of pilocarpine might reduce the risk. This study describes the risk factors of severe radiation-induced oral mucositis in oral cancer patients and shows the possibility of risk reduction by pilocarpine. This information could help patients avoid painful mucositis.
Sections du résumé
BACKGROUND/PURPOSE
OBJECTIVE
Radiotherapy for head and neck cancer often causes severe oral mucositis. The purpose of this retrospective study was to further examine the risk factors for developing severe oral mucositis in patients with oral cancer undergoing radiotherapy as a compliment to a previous study performed by our group.
MATERIALS AND METHODS
METHODS
A total of 181 patients with oral cancer undergoing radiotherapy were enrolled in the study. The association between a number of potential risk factors and grade 3 oral mucositis were analyzed using the cox proportional hazard model and a logistic regression analysis.
RESULTS
RESULTS
Grade 3 oral mucositis occurred in 56 patients. The cox proportional hazard model analysis revealed that those with lower hemoglobin levels, concurrent cisplatin and cetuximab administration, and a larger number of teeth showed a significantly higher incidence of severe oral mucositis. Logistic regression analysis revealed that patients who had lower hemoglobin levels, received concurrent cisplatin or cetuximab treatment, and were not administered pilocarpine showed a significantly higher incidence of severe oral mucositis. The presence of teeth may stimulate the oral mucosa and become a risk factor for mucositis, and the administration of pilocarpine might reduce the risk.
CONCLUSION
CONCLUSIONS
This study describes the risk factors of severe radiation-induced oral mucositis in oral cancer patients and shows the possibility of risk reduction by pilocarpine. This information could help patients avoid painful mucositis.
Identifiants
pubmed: 34484592
doi: 10.1016/j.jds.2021.01.009
pii: S1991-7902(21)00009-X
pmc: PMC8403800
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1241-1246Informations de copyright
© 2021 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V.
Références
Support Care Cancer. 2020 Mar;28(3):1069-1075
pubmed: 31177394
J Support Oncol. 2006 May;4(5):252-8
pubmed: 16724649
Radiother Oncol. 2016 Jul;120(1):13-20
pubmed: 27113797
Cancer. 2014 May 15;120(10):1453-61
pubmed: 24615748
Int J Oral Maxillofac Surg. 2012 Feb;41(2):225-38
pubmed: 22071451
Cancer Chemother Pharmacol. 2018 Mar;81(3):549-554
pubmed: 29383483
Adv Clin Exp Med. 2017 Dec;26(9):1351-1358
pubmed: 29442455
Int J Oral Maxillofac Surg. 2019 Jul;48(7):857-864
pubmed: 30611598
Med Oral Patol Oral Cir Bucal. 2014 Sep 01;19(5):e444-50
pubmed: 24608218